Arvinas, Inc. - Common Stock (ARVN)
7.2300
-2.3900 (-24.84%)
NASDAQ · Last Trade: May 2nd, 2:57 AM EDT
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Via Chartmill · May 1, 2025
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · May 1, 2025

Via Benzinga · February 12, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.
Via Chartmill · May 1, 2025
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via Chartmill · May 1, 2025
Via Benzinga · May 1, 2025
Via Benzinga · April 30, 2025
Arvinas' ARV-102 reduced LRRK2 protein in a Phase 1 trial, showing promising safety and pharmacodynamic outcomes for Parkinson's and PSP treatment.
Via Benzinga · April 4, 2025

Via Benzinga · March 12, 2025

Via Benzinga · March 12, 2025

The companies are looking to use protein degradation to take on some forms of breast cancer.
Via Investor's Business Daily · March 11, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · March 11, 2025

Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.
Via Benzinga · March 11, 2025
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the gap up and gap down stocks in today's session.
Via Chartmill · March 11, 2025
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via Chartmill · March 11, 2025

Via Benzinga · February 12, 2025